Cancel
Encoded Therapeutics
Encoded Therapeutics Employees
7 people indexed:
-
8i9q43.8fkyfz@lgflz0l.08i Sign up to see email
-
wvxp8163.44b26sxu8@u9xkhu4.h0b Sign up to see email
-
Jennifer Holmes
General Counsel, Chief Compliance Officer & Corporate Secretary
wxuu03u3.4tapxp@uyyptu1.ubw Sign up to see emailvqpgqgbq.2xqk2q@439k00p.yxa Sign up to see email -
Kartik Ramamoorthi
Co-founder, Chief Executive Officer & Board Member
sywus6.6ff2658zb5u@222p504.wj7 Sign up to see emailwvzq93.wv85q8sy76p@9y9865j.qgx Sign up to see email -
51z601z5x.qyxr9x01@gfj76pq.fyx Sign up to see email
-
g8f.1v8t@wv3phv1.5tb Sign up to see email
-
Stephanie Tagliatela
Co-founder, Chief Scientific Officer & Board Member
rykuvqy74.u03v0kx26x@vqf4553.bvw Sign up to see email7k0qj0fu6.05w0kf5w3w@80u9vb5.7v6 Sign up to see email
Encoded Therapeutics Company Information
Encoded Therapeutics is a biotechnology company specializing in the development of precision gene therapies for pediatric central nervous system (CNS) disorders. Their flagship program, ETX101, is aimed at treating Dravet syndrome, a severe developmental and epileptic encephalopathy, by modulating the SCN1A gene in a cell-selective manner. This approach seeks to address the root cause of the syndrome. Encoded Therapeutics is also conducting the ENVISION study, a natural history study to better understand the progression of Dravet syndrome in affected children. The company has received regulatory approvals for ETX101, including UK CTA approval and US IND clearance, positioning it as a promising gene therapy candidate for Dravet syndrome. Beyond ETX101, Encoded Therapeutics is developing a pipeline of potential therapies for other pediatric CNS disorders, as well as treatments for liver, metabolic, and cardiovascular diseases. The company leverages a novel targeting and regulation platform to enhance the specificity and potency of its gene therapies. Encoded Therapeutics is headquartered in South San Francisco, CA, and maintains a research facility in Research Triangle Park, NC.
Report inaccurate information
Report inaccurate information
